You can buy Peminib at the lowest price at Nextgen.ooo online pharmacy. Pemigatinib is a kinase inhibitor used to treat locally advanced or metastatic unresectable cholangiocarcinoma in previously treated adult patients.
 
Pemigatinib is a small molecule kinase inhibitor with antitumor activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signaling pathways in tumor cells. FGFRs have attracted attention as potential therapeutic targets in certain cancers because FGFR gene alterations have been observed in a wide range of cancers, including bladder, breast, ovarian, prostate, endometrial, lung, and gastric cancers. Dysregulation of the FGFR signaling pathway can lead to the development of oncogenes and tumor-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and cell death evasion.
 
In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements detected by an FDA-approved test. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary malignancy of the liver. This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, accounting for 13% of all cancer deaths worldwide. With increasing research into the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drugs, recent studies indicate that up to 45% of patients with intrahepatic cholangiocarcinoma have gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins. The FDA-approved indication for pemigatinib was granted accelerated approval based on overall response rates and duration of response in premarketing clinical trials. Pemigatinib is marketed under the brand name Pemazyre and is available as an oral tablet.